The JAK2 V617F mutation is found in patients with blood-related diseases such as polycythemia vera, essential thrombocythemia and myelofibrosis. Ruxolitinib is effective as a JAK inhibitor, making it a prognostic factor in determining drug response. Detection of the JAK2 V617F mutation facilitates the classification of patients with MPD (myeloproliferative disease) into three levels of diagnostic certainty (possible, probable and definitive) and to determine which signal transduction therapy is appropriate for each patient. In addition, the WHO (World Health Organization) has recommended JAK2 V617F mutation testing as a clinical trial.
PNAClamp™ Mutation Detection Kit JAK2
For the detection of JAK2 mutations in tissue biopsies
Cat. No. PNAC-6001
Other products
PNAClamp™ Mutation Detection Kit IDH1
For the detection of IDH1 mutations in tissue biopsies Cat....
ExcelTaq™ 5X Fluorescent PCR Master Mix, 200 Rxn – TP1260
ExcelTaq ™ 5X Fluorescent PCR Master Mix is a ready-to-use...
EZ-10 spin column Total RNA Minipreps super kit (BS784-250PREPS)
Kit for rapid isolation of total RNA from various organisms....
PCR 96-well plate
PCR 96-well plate